Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon

Inclusion Criteria: * obtained voluntary informed consent for participation in the clinical study * presence of systemic scleroderma features satisfied to criteria of American College of Rheumatology classification * presence at least one active digital ulcer at baseline Exclusion Criteria: * presence of another systemic connective tissue disease; * absence at least one active digital ulcer at baseline; * smoking within 3 months or smoking cessation using nicotine products; * subjects currently taking sildenafil, tadalafil or vardenafil; * history of sympathectomy over previous 12 months * not able or unwilling to give voluntary informed consent for the study or follow requirements of the clinical study; * decompensated chronic visceral diseases; * clinically significant laboratory abnormalities; * HIV, HBV and HCV antibodies in serum; * alcohol or drug addiction; * participation in other clinical studies (or administration of study products) within 3 months prior the study; * conditions limiting study compliance (dementia, psycho-neurological diseases, drug addiction, alcoholism, etc.); * malignancies including post-surgical period with chemo- and (or) radiation therapy); * vascular malformations; * pregnancy or breastfeeding.